Cereno Scientific to present CS014’s preclinical data at top European cardiology congress ESC Congress 2022

Cereno Scientific (XSAT: CRNO B) today announced that an abstract on preclinical drug candidate CS014 has been accepted at the ESC Congress 2022 hosted by the European Society of Cardiology in Barcelona, Spain, on August 26-29. The abstract has been selected for an oral moderated poster presentation and is titled “CS014 is a novel HDAC inhibitor regulating platelet activity, fibrinolysis and clot stability for prevention of thrombosis without increased risk of bleeding.” It will be presented by Dr. Michael Holinstat, lead of Cereno’s preclinical development programs at University of Michigan and Director of Translational Research at Cereno.

“It is great to have our abstract selected as an oral moderated poster presentation among many other submissions. It is a testament to the path and direction we are developing CS014 in and the results yielded in the preclinical development program to date,” said Sten R. Sörensen, CEO at Cereno. “Together with the data from our other preclinical candidate CS585, we have two strong drug candidates demonstrating effect in thrombosis prevention without increased risk of bleeding  – thrombosis being a key mechanism in many complications in cardiovascular disease.”

The abstract titled “CS014 is a novel HDAC inhibitor regulating platelet activity, fibrinolysis and clot stability for prevention of thrombosis without increased risk of bleeding” was authored by M. Holinstat, R. Adili, L. Stanger, T. Hoang, S. Lambert and N. Rhoads at University of Michigan, Ann Arbor, United States of America and; B. Dahlöf and N. Bergh at Cereno and University of Gothenburg, Gothenburg, Sweden. The abstract has been selected to be presented as a 3-minute oral moderated poster presentation by Dr. Michael Holinstat.

The ESC Congress 2022 is organized by the European Cardiology Society (ESC). This year, the congress celebrates 70 years of ESC Congresses and brings the latest in cardiovascular science and up-to-date education to the global cardiology community. The congress focuses on key elements relevant for global cardiovascular healthcare professionals such as innovative scientific updates from late-breaking clinical trials and ground-breaking studies, as well as important content for clinical practice and research.

In addition to the onsite oral presentation, the abstract will also be featured on the online congress platform Research Gateway, the dedicated section to abstracts and clinical cases. After the congress, the abstract will be published in the online abstract supplement of the European Heart Journal; and both the abstract and the presentation will be available on ESC365, the cardiology knowledge hub.

Drug candidate CS014 is a novel HDAC (histone deacetylase) inhibitor with epigenetic modulation properties. It was acquired by Cereno from Emeriti Bio in 2019 and has since been developed in a collaboration between Cereno and Emeriti Bio. Since 2021, a full preclinical development program (the HDACi Program) has been ongoing in collaboration with the University of Michigan under the lead of Dr. Michael Holinstat, Director Translational Research at Cereno and Associate professor of Internal Medicine, Division of CV Medicine at University of Michigan. The program intends to fulfill requirements to start first-in-human clinical trials for this novel HDACi treatment in 2023.

For further information, please contact:

Daniel Brodén, CFO
Phone: +46 768 66 77 87
Email: info@cerenoscientific.com
http://www.cerenoscientific.com/

About Cereno Scientific AB

Cereno Scientific is a clinical stage biotech company within cardiovascular disease. The lead drug candidate, CS1, is a Phase II candidate in development for the treatment of the rare disease pulmonary arterial hypertension (PAH). CS1 is an HDAC (histone deacetylase) inhibitor that acts as an epigenetic modulator with pressure-reducing, reverse-remodeling, anti-fibrotic, anti-inflammatory and anti-thrombotic properties, all relevant for PAH. A clinical Phase II study is ongoing to evaluate CS1’s safety, tolerability and efficacy in patients with PAH. A collaboration agreement with global healthcare company Abbott allows Cereno to use their cutting-edge technology CardioMEMS HF System in the study. Cereno also has two promising preclinical drug candidates in development through research collaborations with the University of Michigan. Targeted at treating cardiovascular disease, drug candidate CS585 is a stable, selective, and potent prostacyclin receptor agonist and drug candidate CS014 is an HDAC inhibitor with epigenetic effects. The company is headquartered in Gothenburg, Sweden, and has a US subsidiary Cereno Scientific Inc. based in Kendall Square in Boston, Massachusetts, US. Cereno is listed on the Swedish Spotlight Stock Market (CRNO B). More information on www.cerenoscientific.com.